Please ensure Javascript is enabled for purposes of website accessibility

Bristol-Myers Squibb Co: Buy the Dip?

By Cory Renauer - Apr 20, 2017 at 10:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The reaction to Opdivo’s recent shortcomings seem overblown. Is Bristol-Myers Squibb stock a buy right now?

Shares of Bristol-Myers Squibb (BMY -0.50%) have slipped about 30% since the company announced a surprising setback for its lead growth driver, Opdivo, last August. More recent missteps in skin and brain cancer trials have analysts scrambling to adjust their peak sales targets for the blockbuster cancer drug, while the big pharma's stock price languishes.

Opdivo's misfortune should raise concerns, but the market's reaction seems out of proportion to the potential financial impact. In terms of market capitalization, Bristol-Myers Squibb is worth about $39 billion less at recent prices than it was at the beginning of last August.

Buy and sell signs.

Image source: Getty Images.

The depressed stock has piqued the interest of legendary activist investor Carl Icahn. Rather than just follow him blindly, let's take a closer look at the source of pessimism to see if the big pharma stock is a buy on the dip.

Fall from grace

Since earning the drug's first approval at the end of 2014, Bristol has deftly expanded Opdivo's addressable population to include patients with head and neck, skin, lung, kidney, and bladder cancers, plus Hodgkin lymphoma. In its second full year post-approval, the drug generated a stunning $3.77 billion in sales, and hasn't slowed down yet. Fourth-quarter sales suggest a $5.24 billion annual run rate.

Lung cancer isn't the most common malignancy, but it is the deadliest. It's also ripe for better therapies, which explains why the market hammered Bristol's stock in response to Opdivo's failure to outperform age-old chemotherapy among newly diagnosed, untreated patients with the most common form of lung cancer. Merck & Co. rubbed salt into Bristol's wounds by announcing an FDA approval for its drug of the same class in the first-line lung cancer setting.

Merck's Keytruda isn't the only drug of the same class that Opdivo will need to contend with in the future. More recently launched Tecentriq, from Roche, and Bavencio, from Pfizer (PFE 0.79%), also prevent tumor cells from exploiting the same checkpoint to evade immune system attacks.

Pfizer's Bavencio recently entered the commercial stage as the only drug approved for Merkel cell skin cancer, and Tecentriq has launched into two of Opdivo's indications. Bristol's checkpoint inhibitor now competes with Roche's for lung and bladder cancer patients with disease progression on or after standard chemotherapy.

Lab technician with a pipette.

Image source: Getty Images.

Now the good news

Opdivo isn't the only drug driving growth for Bristol-Myers Squibb. Eliquis is an oral blood thinner that's rapidly gaining popularity. Bristol markets it in partnership with Pfizer, and its share of sales last year bounded 80% higher than the previous year to $3.34 billion.

Although emerging competition probably won't allow Opdivo sales to continue along their current trajectory, they're not about to slide either. In fact, the average Wall Street analyst following Bristol-Myers expects its bottom line to expand at an 11.8% annual rate over the next five years.

You would expect shares of a company growing this quickly to command an above-average price-to-earnings ratio, but that just isn't the case. At recent prices Bristol-Myers shares can be purchased for just 20.2 times trailing earnings, while the average stock in the benchmark S&P 500 currently trades at around 24.5 times trailing earnings.

Cautious investors who are after a steady dividend income will appreciate a juicy 2.9% yield at recent prices. Last year the company used only 57% of profits to make those payments, which should allow the payout to rise in step with bottom-line growth. With long-term double-digit growth on the horizon, and a big yield to begin with, this may be one of the best dividend-paying pharmaceutical stocks you can buy right now.

Icahn see a merger on the horizon

While you shouldn't follow billionaires blindly, the recent addition of Carl Icahn to the company's list of activist shareholders bodes well for the stock's price going forward. The octogenarian has a long history of making big bets on drugmakers, then pestering management to increase shareholder value.

Icahn won't be alone in this endeavor. Jana Partners LLC already set some important wheels in motion. Following discussions with the activist investor group this February, Bristol-Myers added three independent directors to its board and initiated a $2 billion accelerated share-buyback program.

If Icahn stays true to form, though, he won't be satisfied with buybacks and dividends. Years ago he was instrumental in the sale of Imclone Systems to Eli Lilly, and Sanofi's acquisition of Genzyme. Genzyme and Imclone shareholders benefited from the premiums paid by their current owners, and with a bit of luck Bristol could be next.

At a recent market cap of about $88.1 million, there aren't many potential suitors to choose from. Even if Icahn doesn't succeed in steering the company toward a sale, increased focus on shareholder benefits is a big plus. Factor improved corporate governance in with a nice dividend and expectations of double-digit growth in the years ahead, and it sure looks like Bristol-Myers Squibb stock is a buy at recent prices.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$78.31 (-0.50%) $0.39
Pfizer Inc. Stock Quote
Pfizer Inc.
$51.06 (0.79%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.